INTS · XBRL financial data

Intensity Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (INTS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,352	1,801*	2,815	3,563	2,151	1,967*	2,189	1,541	1,553	1,502*	1,195	1,833
General and administrative	1,139	1,551*	1,928	1,506	1,419	1,236*	1,205	1,164	1,180	1,638*	1,331	1,251
Total operating expenses	2,491	3,353*	4,743	5,069	3,570	3,203*	3,394	2,705	2,733	3,140*	2,526	3,084
Operating income (loss)	(2,491)	(3,353)*	(4,743)	(5,069)	(3,570)	(3,203)*	(3,394)	(2,705)	(2,733)	(3,140)*	(2,526)	(3,084)
Interest income	148	176*	140	98	48	28*	15	17	59	88*	94	77
Interest expense	0*	(0)*	0	0	0	0*	—	—	—	—	—	—
Other income (expense)	14	—	0	0	9	(6)*	32	151	3	1*	(2)	0
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(2,330)	(3,171)*	(4,603)	(4,971)	(3,513)	(3,181)*	(3,347)	(2,537)	(2,671)	(3,051)*	(2,434)	(3,007)
Earnings per share, basic‡ USD per share	(4.25)	—	(8.50)	(9.00)	(6.25)	(5.50)*	(5.50)	(3.25)	(1.50)	—	(0.96)	(1.11)
Earnings per share, diluted‡ USD per share	(4.25)	—	(8.50)	(9.00)	(6.25)	(5.50)*	(5.50)	(3.25)	(1.50)	—	(0.96)	(1.11)
Weighted average shares, basic‡ thousands of shares	546	—	548	548	552	576*	607	755	1,722	—	2,534	2,707
Weighted average shares, diluted‡ thousands of shares	546	—	548	548	552	576*	607	755	1,722	—	2,534	2,707

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (February 2026); filings made before it reported them unadjusted.
† Share count changed about 1/24 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 27x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (INTS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,694	8,556	7,458	3,241	2,782	2,590	929	2,216	7,067	11,921	10,245	9,529
Marketable securities	8,955	—	—	—	—	—	—	—	—	—	—	—
Marketable securities, non-current	8,955	—	—	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	—	688	672	1,116	1,005	773	722	822	1,119	788	661	1,700
Total current assets	16,635	15,464	11,169	7,440	3,787	3,363	1,651	3,038	8,186	12,709	10,906	11,229
Right-of-use asset	153	147	141	135	128	122	116	109	103	96	89	82
Total assets	16,816	17,295	12,408	8,673	5,213	4,783	3,065	4,443	9,585	14,101	12,291	11,521
Accounts payable	358	3,048	1,219	1,919	540	1,219	1,586	1,193	1,684	583	636	1,009
Accrued liabilities	355	891	1,274	1,258	1,749	508	1,014	941	561	1,532	1,574	1,203
Total current liabilities	724	3,959	2,519	3,204	2,317	1,755	2,629	2,164	2,276	2,146	2,242	2,245
Lease liability, non-current	145	138	131	124	117	110	102	95	87	79	70	62
Total liabilities	905	4,133	2,686	3,328	2,434	1,865	2,731	2,259	2,363	2,225	2,312	2,307
Accumulated deficit	(47,343)	(50,515)	(55,118)	(60,089)	(63,602)	(66,783)	(70,130)	(72,667)	(75,338)	(78,389)	(80,823)	(83,830)
Total stockholders' equity	15,911	13,162	9,722	5,345	2,779	2,918	334	2,184	7,222	11,876	9,979	9,214
Total liabilities and equity	16,816	17,295	12,408	8,673	5,213	4,783	3,065	4,443	9,585	14,101	12,291	11,521
Common shares outstanding (cover page)‡ thousands of shares	548	548	548	551	555	607	736	1,882	2,403	102	2,703	3,265

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (February 2026); filings made before it reported them unadjusted.
† Share count changed about 1/24 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 27x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (INTS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,330)	(3,171)*	(4,603)	(4,971)	(3,513)	(3,181)*	(3,347)	(2,537)	(2,671)	(3,051)*	(2,434)	(3,007)
Stock-based compensation	351*	423*	1,155	591*	483*	844*	435	644*	471*	450*	387	387*
Net cash from operating activities	(5,119)*	(947)*	(4,366)	(4,214)*	(3,972)*	(2,668)*	(1,989)	(2,456)*	(2,387)*	(2,401)*	(1,826)	(2,340)*
Net cash from investing activities	(8,844)*	2,821*	3,260	(6)*	3,100*	0*	0	0*	0*	0*	—	—
Proceeds from issuing common stock	—	—	0	—	—	—	345	—	—	—	—	—
Proceeds from long-term debt	0*	(13)*	0	0*	0*	0*	—	—	—	—	—	—
Net cash from financing activities	20,521*	(12)*	8	3*	413*	2,476*	328	3,743*	7,238*	7,255*	150	1,624*
Net change in cash	6,558*	1,862*	(1,098)	(4,217)*	(459)*	(192)*	(1,661)	1,287*	4,851*	4,854*	(1,676)	(716)*

† Share count changed about 1/24 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 27x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.